title: Propranolol and venlafaxine for vestibular migraine prophylaxis: A randomized controlled trial.
abstract: OBJECTIVE
  We compared the effectiveness of venlafaxine and propranolol for the prophylaxis of vestibular migraine (VM).
  
  
  METHODS
  Prospective, randomized, controlled clinical trial.
  
  
  METHODS
  Sixty-four subjects with definite VM were enrolled. The subjects were randomly assigned to receive propranolol (group P, n = 33) or venlafaxine (group V, n = 31) for VM prophylaxis. Dizziness Handicap Inventory (DHI) scores, the Vertigo Severity Score (VSS), and the number of vertiginous attacks were recorded before and 4 months after treatment. The Beck Anxiety Inventory (BAI) and Beck Depression Inventory (BDI) scores were also recorded to monitor the resolution of psychiatric symptoms.
  
  
  RESULTS
  At 4 months after treatment, the DHI total score decreased from 55.8 ± 2.7 to 31.3 ± 3.7 and from 50.9 ± 2.5 to 19.9 ± 2.9 (P < .001), the mean number of total vertiginous attacks decreased from 12.6 ± 1.8 to 1.9 ± 0.7 and from 12.2 ± 1.8 to 2.6 ± 1.1 (P < .001), and VSS decreased from 7.3 ± 0.3 to 2.1 ± 0.4 and from 7.9 ± 0.3 to 1.8 ± 0.5 (P < .001) in groups P and V, respectively. However, the treatment effects were similar in both groups (P > .05). BAI scores significantly decreased in both groups, whereas BDI scores decreased only in group V.
  
  
  CONCLUSIONS
  This study provided evidence that venlafaxine and propranolol show equal effectiveness as prophylactic drugs for ameliorating vertiginous symptoms in VM patients. However, venlafaxine may be superior to propranolol in ameliorating depressive symptoms.
authors.affiliation: Department of Otorhinolaryngology, Istanbul, Turkey.
authors.forename: Mehti
authors.initials: M
authors.lastname: Salviz
authors.affiliation: Department of Otorhinolaryngology, Istanbul, Turkey.
authors.forename: Turgut
authors.initials: T
authors.lastname: Yuce
authors.affiliation: Department of Neurology, Haseki Research and Training Hospital, Istanbul, Turkey.
authors.forename: Hurtan
authors.initials: H
authors.lastname: Acar
authors.affiliation: Department of Otorhinolaryngology, Istanbul, Turkey.
authors.forename: Abdullah
authors.initials: A
authors.lastname: Karatas
authors.affiliation: Department of Otorhinolaryngology, Istanbul, Turkey.
authors.forename: R Murat
authors.initials: RM
authors.lastname: Acikalin
mesh_terms: D000293:Adolescent; D000328:Adult; D018687:Antidepressive Agents, Second-Generation / Q000627:therapeutic use*; D003863:Depression / Q000188:drug therapy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000517:prevention & control* / Q000523:psychology; D011433:Propranolol / Q000627:therapeutic use*; D011446:Prospective Studies; D014665:Vasodilator Agents / Q000627:therapeutic use*; D000069470:Venlafaxine Hydrochloride / Q000627:therapeutic use*; D015837:Vestibular Diseases / Q000188:drug therapy*
chemical_list: D018687:Antidepressive Agents, Second-Generation; D014665:Vasodilator Agents; D000069470:Venlafaxine Hydrochloride; D011433:Propranolol
keywords: Anxiety; depression; dizziness handicap inventory; migraine; prophylaxis; vertigo